Growth suppression of human lung cancer cells and implanted tumors by adenovirus-mediated transfer of the PTEN gene.
This study examined the effects of a recombinant adenovirus Ad-PTEN-EGFP on the proliferation of A549 cells, a human lung carcinoma cell line, in vitro and on the growth of the implanted tumors in the nude mice in vivo, explored the underlying mechanisms and evaluated the in vitro transfection efficiency of Ad-PTEN-EGFP into A549 cells. The expression of Ad-PTEN-EGFP in the A549 cells was determined. The proliferation and the apoptosis rates of the A549 cells with Ad-PTEN-EGFP transfection or not was detected by MTT and flow cytometry. Ad-PTEN-EGFP at different doses was injected intratumorally to the tumor-bearing mice induced by the A549 cells. Tumor sizes were measured on an alternate day. After all the mice were sacrificed, the implanted tumors were removed for routine histological examination, weight test, HE staining and immunohistochemical staining. The expressions of Bax, P16 and P53 in the tumor tissues and those of caspase-3, CD34 and VEGF in the mouse sera were detected. Tumor cell apoptosis was measured by TUNEL method. The results showed that the vitality of the A549 cells after transfection with Ad-PTEN-EGFP declined. The expression of green fluorescent protein was observed under fluorescent microscope. The transfection rate was in excess of 50%. The mRNA and protein expression of PTEN in the transfected cells was confirmed. The proliferation rate of the transfected cells was significantly decreased when compared with that of the non-transfected cells (P<0.05). The number of the apoptosis cells was increased in the transfected cells (P<0.05). The models of implanted tumors were successfully established by injection of the A549 cells in the flank of Balb/c nude mice. Administration of Ad-PTEN-EGFP to the tumor-bearing nude mice resulted in a suppression of tumor growth. There were statistically significant differences in the tumor weight and tumor volume between the Ad-PTEN-EGFP-treated group and the control groups (P<0.05). In contrast to those in the control groups, tumor tissues in the Ad-PTEN-EGFP-treated group were shown to have typical extensive vacuolar degeneration and massive hemorrhagic necrosis. Apoptotic bodies were also observed in the tumor cells. The expressions of Bax, caspase-3 and P16 were increased (P<0.05) while those of CD34, VEGF and P53 decreased (P<0.05) in the Ad-PTEN-EGFP-treated group. It is concluded that Ad-PTEN-EGFP could induce the apoptosis of the A549 cells and inhibit their proliferation. And it could also substantially suppress the tumor growth in the tumor-bearing nude mice and induce apoptosis of the tumor cells as well. These findings carry significant implications for adenovirus vector-based PTEN gene therapies for lung cancers.
Chen
Zhixiong
Z
Department of Geriatrics, People's Hospital of Wuhan University, Wuhan, 430060, China. czxdd@msn.com
Yang
Jiong
J
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D000256:Adenoviridae / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D017209:Apoptosis / Q000235:genetics*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015316:Genetic Therapy; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D014162:Transfection
D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; C485184:enhanced green fluorescent protein; D049452:Green Fluorescent Proteins; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6199-204
10339565
Oncogene. 2002 Jan 10;21(2):319-27
11803475
Am J Pathol. 2001 Jun;158(6):2097-106
11395387
Diagn Mol Pathol. 2003 Sep;12(3):160-5
12960698
J Biol Chem. 2001 Sep 21;276(38):35786-93
11448956
Pathol Int. 2004 Jan;54(1):10-5
14674989
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2110-5
10051603
Cancer Res. 1998 Jun 1;58(11):2331-4
9622068
Gene Ther. 2003 Nov;10(23):1961-9
14528320
Ai Zheng. 2004 Jun;23(6):662-6
15191666
Gene Ther. 2003 Sep;10(19):1636-42
12923562
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50
9560261
Cell Commun Adhes. 2004 Jan-Feb;11(1):1-11
15500293
Science. 1997 Mar 28;275(5308):1943-7
9072974
Oncogene. 2003 Nov 6;22(50):8195-204
14603260
Cancer Lett. 2001 Oct 22;172(1):83-91
11595133
Cancer Res. 1997 Dec 1;57(23):5221-5
9393738